Recently, high-throughput RNAi screen identified CHEK1 as target for sensitizing ovarian cancer cells to cisplatin and pancreatic cancer cells to gemcitabine [48], [49] as well as mesothelioma cells to doxorubicin [50]. The gene discussed is CHEK1; the disease is familial pancreatic carcinoma.